Details for Patent: 10,933,053

Which drugs does patent 10,933,053 protect, and when does it expire?

Patent 10,933,053 protects ZERBAXA and is included in one NDA.

This patent has seven patent family members in four countries.

Summary for Patent: 10,933,053

Patent landscape, scope, and claims:

Title:	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Abstract:	Disclosed are methods of administering cephalosporin/tazobactam to human patients with end stage renal disease undergoing hemodialysis and suffering from a complicated intra-abdominal infection or a complicated urinary tract infection.
Inventor(s):	Krishna; Gopal (Stow, MA), Chandorkar; Gurudatt (Waltham, MA), Hershberger; Elham (Lexington, MA), Miller; Benjamin (Cambridge, MA), Xiao; Alan (Lexington, MA)
Assignee:	MERCK SHARP & DOHME CORP. (Rahway, NJ)
Application Number:	16/525,458
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,933,053

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes						TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes						TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

International Family Members for US Patent 10,933,053

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014233637
Australia	2016202199
Australia	2017279686